 | Up a level |
Journal Article
Dreger, P., Boumendil, A., Koster, L., Scheid, C., Passweg, J., Veelken, H., Cahn, Y., Collin, M., Wilson, K., Bazarbachi, A., Mayer, J., Corradini, P., Hunault-Berger, M., Parody Porras, R., Gribben, J., Bittenbring, J., Wolff, D., Charbonnier, A., Cambier, N., Montoto, S., Kroeger, N. and Schetelig, J. (2017). No evidence for an increased GVHD risk associated with post-transplant Idelalisib given for relapse of chronic lymphocytic leukemia or lymphoma: First results of a survey by the EBMT chronic malignancy and lymphoma working parties. Bone Marrow Transplant., 52. S. S424 - 2. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Dreger, P., Michallet, M., Bosman, P., Sobh, M., Boumendil, A., Nagler, A., Scheid, C., Cornelissen, J., Mueller, L., Niederwieser, D., Vandenberghe, E., Scortechini, I., Schoemans, H., Andersen, N., Finke, J., Russo, D., Ljungman, P., Passweg, J., van Gelder, M., Durakovic, N., Labussiere, H., Berg, T., Wulf, G., Bethge, W., Stilgenbauer, S., Mordini, N., Schaap, M., Fox, C., Kroeger, N., Montoto, S. and Schetelig, J. (2017). Ibrutinib for bridging to allogeneic hematopoietic stem cell transplantation (alloHCT) in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) is safe and effective: Updated results of a study by the EBMT Chronic Malignancy and Lymphoma Working Parties, the French Cooperative Group for CLL, and the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant., 52. S. S99 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Greinix, H., Beohou, E., van der Werf, S., Niederwieser, D., Blaise, D., Dreger, P., Arnold, R., Meijer, E., Sengeloev, H., Cornelissen, J., Hallek, M., Socie, G., Chevallier, P., Ganser, A., Milpied, N., Maertens, J., Petersen, E., Afanasyev, B., Ehninger, G., Fegueux, N., Jindra, P., Kroeger, N., Montoto, S., Nagler, A. and Duarte, R. (2017). Impact of ATG use on the outcome of patients with hematological malignancies undergoing reduced-intensity conditioning for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant., 52. S. S61 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Jagasia, M., Beohou, E., van der Werf, S., Niederwieser, D., Dreger, P., Meijer, E., Chevallier, P., Sengeloev, H., Blaise, D., Petersen, E., Cornelissen, J. J., Ehninger, G., Gribben, J., Caballero, D., Beguin, Y., Hallek, M., Jindra, P., Fanin, R., Delage, J., Maertens, J., Gedde-Dahl, T., Montoto, S., Kroger, N., Greinix, H. and Duarte, R. (2017). Addition of rituximab in reduced intensity conditioning regimens for B-cell malignancies does not influence transplant outcomes: an EBMT registry analyses. Bone Marrow Transplant., 52. S. S83 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365